-
Something wrong with this record ?
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination
R. Chlibek, I. Anca, F. André, M. Bakir, I. Ivaskeviciene, A. Mangarov, Z. Mészner, P. Perenovska, R. Prymula, D. Richter, N. Salman, P. Simurka, E. Tamm, N. Toplak, V. Usonis,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest)
from 2002-01-01 to 2 months ago
Family Health Database (ProQuest)
from 2002-01-01 to 2 months ago
Health Management Database (ProQuest)
from 2002-01-01 to 2 months ago
Public Health Database (ProQuest)
from 2002-01-01 to 2 months ago
- MeSH
- Influenza, Human prevention & control MeSH
- Adult MeSH
- Disease Outbreaks prevention & control MeSH
- Infant MeSH
- Humans MeSH
- Child, Preschool MeSH
- Pregnancy MeSH
- Vaccination MeSH
- Influenza Vaccines administration & dosage MeSH
- Influenza A Virus, H1N1 Subtype immunology MeSH
- Health Planning Guidelines MeSH
- Health Personnel MeSH
- Check Tag
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Child, Preschool MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
The 2009 influenza A(H1N1) pandemic is markedly different from seasonal influenza with the disease affecting the younger population and a larger than expected number of severe or fatal cases has been seen in pregnant women, obese people and in people who were otherwise healthy. In Europe, influenza activity caused by the 2009 influenza A(H1N1) virus has passed the winter peak with nearly all countries now reporting lower influenza activity. However, although the rate of 2009 pandemic influenza A(H1N1) is declining, fatal cases continue to be reported and the future is hard to predict. The most effective protection against influenza is vaccination and increasing vaccine coverage is the only way to eliminate uncertainties regarding possible future waves of 2009 pandemic influenza A(H1N1). Recommendations have been developed for several central European countries but there is no clear or uniform definition with respect to priority groups or age groups who should receive vaccination. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the vaccination of adults and children against 2009 pandemic influenza A(H1N1). CEVAG recommends vaccination of all health-care workers, pregnant women, children > or = 6 months and <2 years of age and people with chronic medical conditions as a first priority.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025799
- 003
- CZ-PrNML
- 005
- 20121207112159.0
- 007
- ta
- 008
- 120817e20100407ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.vaccine.2010.03.072 $2 doi
- 035 __
- $a (PubMed)20380902
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Chlibek, Roman $u Faculty of Military Health Sciences, University of Defense, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. chlibek@pmfhk.cz
- 245 10
- $a Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination / $c R. Chlibek, I. Anca, F. André, M. Bakir, I. Ivaskeviciene, A. Mangarov, Z. Mészner, P. Perenovska, R. Prymula, D. Richter, N. Salman, P. Simurka, E. Tamm, N. Toplak, V. Usonis,
- 520 9_
- $a The 2009 influenza A(H1N1) pandemic is markedly different from seasonal influenza with the disease affecting the younger population and a larger than expected number of severe or fatal cases has been seen in pregnant women, obese people and in people who were otherwise healthy. In Europe, influenza activity caused by the 2009 influenza A(H1N1) virus has passed the winter peak with nearly all countries now reporting lower influenza activity. However, although the rate of 2009 pandemic influenza A(H1N1) is declining, fatal cases continue to be reported and the future is hard to predict. The most effective protection against influenza is vaccination and increasing vaccine coverage is the only way to eliminate uncertainties regarding possible future waves of 2009 pandemic influenza A(H1N1). Recommendations have been developed for several central European countries but there is no clear or uniform definition with respect to priority groups or age groups who should receive vaccination. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the vaccination of adults and children against 2009 pandemic influenza A(H1N1). CEVAG recommends vaccination of all health-care workers, pregnant women, children > or = 6 months and <2 years of age and people with chronic medical conditions as a first priority.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a epidemický výskyt choroby $x prevence a kontrola $7 D004196
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdravotnický personál $7 D006282
- 650 _2
- $a zdravotnické plánování - směrnice $7 D006287
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a virus chřipky A, podtyp H1N1 $x imunologie $7 D053118
- 650 _2
- $a vakcíny proti chřipce $x aplikace a dávkování $7 D007252
- 650 _2
- $a chřipka lidská $x prevence a kontrola $7 D007251
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a vakcinace $7 D014611
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Anca, Ioana $7 gn_A_00005904
- 700 1_
- $a André, Francis $7 gn_A_00006356
- 700 1_
- $a Bakir, Mustafa
- 700 1_
- $a Ivaskeviciene, Inga
- 700 1_
- $a Mangarov, Atanas
- 700 1_
- $a Mészner, Zsófia
- 700 1_
- $a Perenovska, Penka
- 700 1_
- $a Prymula, Roman
- 700 1_
- $a Richter, Darko
- 700 1_
- $a Salman, Nuran
- 700 1_
- $a Simurka, Pavol
- 700 1_
- $a Tamm, Eda
- 700 1_
- $a Toplak, Natasa
- 700 1_
- $a Usonis, Vytautas
- 773 0_
- $w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 28, č. 22 (20100407), s. 3758-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20380902 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207112233 $b ABA008
- 999 __
- $a ok $b bmc $g 947841 $s 783145
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 28 $c 22 $d 3758-66 $e 20100407 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
- LZP __
- $a Pubmed-20120817/10/03